You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IHC-confirmed NY-ESO-1 positivity

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor Trial in Nijmegen (PRECIOUS-01)

Recruiting
  • Advanced Solid Tumor
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Oct 26, 2022

Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)

Withdrawn
  • Advanced Solid Tumor
  • TCRT-ESO-A2
  • (no location specified)
Aug 31, 2022

Melanoma Trial in East Melbourne, Heidelberg (NY-ESO-1 ISCOMATRIX® vaccine, Cyclophosphamide)

Completed
Has Results
  • Melanoma
  • East Melbourne, Victoria, Australia
  • +1 more
Oct 3, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Melanoma Trial in Australia, New Zealand, United Kingdom (NY-ESO-1 ISCOMATRIX®, ISCOMATRIX® adjuvant)

Completed
Has Results
  • Melanoma
  • NY-ESO-1 ISCOMATRIX®
  • ISCOMATRIX® adjuvant
  • Camperdown, New South Wales, Australia
  • +14 more
Oct 3, 2022

Tumors Trial in Worldwide (GSK3845097, Cyclophosphamide, Fludarabine)

Terminated
  • Neoplasms
  • New Haven, Connecticut
  • +20 more
Jul 5, 2023

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New York (NY-ESO-1 OLP4, NY-ESO-1 OLP4 +

Completed
Has Results
  • Epithelial Ovarian Cancer
  • +2 more
  • NY-ESO-1 OLP4
  • +2 more
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Soft Tissue Sarcoma Trial in Guangzhou (TAEST16001 cells)

Active, not recruiting
  • Soft Tissue Sarcoma
  • TAEST16001 cells
  • Guangzhou, Guangdong, China
    Xing Zhang
Dec 13, 2022

Unresectable or Metastatic Melanoma Trial in Australia, United States (Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4

Terminated
Has Results
  • Unresectable or Metastatic Melanoma
  • Ipilimumab
  • +3 more
  • New York, New York
  • +4 more
Oct 3, 2022

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Triple Negative Breast Cancer Trial in Los Angeles (biological, procedure, drug)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Aldesleukin
  • +12 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Aug 9, 2023

Advanced Solid Tumors Trial in Chongqing (TC-N201 cells, IL-2, Fludarabine)

Recruiting
  • Advanced Solid Tumors
  • TC-N201 cells
  • +4 more
  • Chongqing, China
    TCRCure Biopharma Ltd.
May 25, 2023

Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)

Not yet recruiting
  • Solid Tumors
  • TCR-T cells
  • +4 more
  • (no location specified)
Dec 12, 2022

Prostate Cancer, Bladder Cancer, NSCLC Trial in New York, Houston (NY-ESO-1 Plasmid DNA Cancer Vaccine)

Completed
Has Results
  • Prostate Cancer
  • +4 more
  • NY-ESO-1 Plasmid DNA Cancer Vaccine
  • New York, New York
  • +1 more
Oct 3, 2022

Ovarian Cancer, NSCLC, ESCC Trial in United States (ASP0739, Pembrolizumab)

Active, not recruiting
  • Ovarian Cancer
  • +3 more
  • Duarte, California
  • +6 more
Jan 21, 2023

Advanced Soft-tissue Sarcoma Trial in Shenzhen (NY-ESO-1 TCR-T)

Recruiting
  • Advanced Soft-tissue Sarcoma
  • NY-ESO-1 TCR-T
  • Shenzhen, Guangdong, China
    Li Yu
Nov 17, 2022

Malignant Tumor Trial in Los Angeles (biological, drug, other, radiation, procedure)

Active, not recruiting
  • Malignant Neoplasm
  • aldesleukin
  • +7 more
  • Los Angeles, California
    University of California at Los Angeles (UCLA )
Dec 1, 2022

Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV Trial in Jerusalem (CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide,

Recruiting
  • Sarcoma, Synovial
  • +8 more
  • CYCLOPHOSPHAMIDE and FLUDARABIN
  • +3 more
  • Jerusalem, Israel
    Hadassah Medical Organization
Mar 15, 2022

Tumors Trial in Worldwide (Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Neoplasms
  • Letetresgene autoleucel (lete-cel, GSK3377794)
  • +2 more
  • Duarte, California
  • +36 more
Oct 28, 2022

Cancer, Tumor Trial in Frankfurt (NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51)

Completed
Has Results
  • Cancer
  • Neoplasm
  • NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51
  • Frankfurt, Germany
    Krankenhaus Nordwest
Oct 3, 2022

Tumors Trial in United States (letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine)

Completed
Has Results
  • Neoplasms
  • letetresgene autoleucel (GSK3377794)
  • +2 more
  • Tampa, Florida
  • +5 more
Oct 31, 2022

Tumors Trial in Worldwide (Letetresgene autoleucel)

Active, not recruiting
  • Neoplasms
  • Letetresgene autoleucel
  • Pittsburgh, Pennsylvania
  • +5 more
Aug 7, 2023

Tumors Trial in United States (NY-ESO-1(c259)T Cells, Fludarabine, Cyclophosphamide)

Completed
Has Results
  • Neoplasms
  • NY-ESO-1(c259)T Cells
  • +2 more
  • Duarte, California
  • +7 more
Jun 9, 2021

Select Advanced Solid Tumors Trial in Canada, United Kingdom, United States (IMCnyeso)

Terminated
Has Results
  • Select Advanced Solid Tumors
  • Aurora, Colorado
  • +11 more
Mar 9, 2022

Soft Tissue Sarcoma Trial in Guangzhou, Beijing (NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy))

Recruiting
  • Soft Tissue Sarcoma
  • NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
  • Guangzhou, Guangdong, China
  • +1 more
Sep 18, 2022